Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease

American Journal of Health-System Pharmacy

Volumn 64, Issue 13 SUPPL., 2007, Pages

  Grabe, Darren W ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Anemia; Continuous erythropoiesis receptor activator; Darbepoetin alfa; Dialysis; Dosage; Dosage schedules; Drugs, investigational; Epoetin alfa; Half life; Hematopoietic agents; Iron; Iron preparations; Kidney diseases; National Kidney Foundation; Protocols

Indexed keywords

ENZYME INHIBITOR; ERYTHROPOIETIN; FERRITIN; FERUMOXYTOL; FG 2216; FG 4592; HEMATIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CONFERENCE PAPER; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; IRON THERAPY; MUSCLE CRAMP; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; THROMBOSIS; TREATMENT DURATION;

EID: 34347391287     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070182     Document Type: Conference Paper

References (42)

1. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006; 47(5 suppl 3):S11-145.
2. National Kidney Foundation. Kidney/Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 suppl 1):S1-266.
3. Procrit package insert. Raritan, NJ: Ortho Biotech Products, L.P.; December 2006.
4. Epogen package insert. Thousand Oaks, CA: Amgen; December 2006.
5. Aranesp package insert. Thousand Oaks, CA: Amgen; December 2006.
6. Hoggard J, Crouch T, McMurray S et al. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis. Curr Med Res Opin. 2006; 22:2023-30.
7. Cleland JG, Sullivan JT, Ball S et al. Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation. J Cardiovasc Pharmacol. 2005; 46:155-61.
8. Ling B, Walczyk M, Agarwal A et al. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol. 2005; 63:327-34.
9. Adamson JW. Iron deficiency and other hypoproliferative anemias. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL, eds. Harrison's Principles of Internal Medicine. 16th ed. New York, NY: McGraw-Hill; 2005:586-92.
10. McEvoy GK, ed. Iron preparations, oral. In: AHFS Drug Information 2007. Bethesda, MD: American Society of Health-System Pharmacists; 2007:1410-7.
11. McEvoy GK, ed. Iron dextran. In: AHFS Drug Information 2006. Bethesda, MD: American Society of Health-System Pharmacists; 2006:1418-21.
12. McEvoy GK, ed. Sodium ferric gluconate. In: AHFS Drug Information 2007. Bethesda, MD: American Society of Health-System Pharmacists; 2007:1418-22.
13. McEvoy GK, ed. Iron sucrose. In: AHFS Drug Information 2007. Bethesda, MD: American Society of Health-System Pharmacists; 2007:1417-8.
14. Zamboni WC, Stewart CE. An overview of the pharmacokinetic disposition of darbepoetin alfa. Pharmacotherapy. 2002; 22(9 pt 2):133S-140S.
15. Nissenson AR, Swan SK, Lindberg JS et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002; 40:110-8.
16. Locatelli F, Villa G, Backs W et al. Aranesp (darbepoetin alfa) maintains hemoglobin levels in hemodialysis patients at extended dosing intervals regardless of previous recombinant human erythropoietin dosing frequency [abstract]. American Society of Nephrology 2004 [PUB254]. J Am Soc Nephrol. 2004;15 (abstracts): 816A
17. Jadoul M, Vanrenterghem Y, Foret M et al. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant. 2004; 19:898-903.
18. Silver MR, Ayus CJ, Dhingra R et al. Once-monthly (QM) Aranesp (darbepoetin alfa) maintains target hemoglobin (Hb) levels in patients with chronic kidney disease who are converting from every-other-week (Q2W) administration. J Am Soc Nephrol. 2005; 16:762A. Abstract SA-PO940.
19. Drug Topics Red Book. Montvale, NJ: Medical Economics; 2003.
20. Bunn HF. New agents that stimulate erythropoiesis. Blood. 2007; 109:868-73.
21. Macdougall IC. Recent advances in erythropoietic agents in renal anemia. Semin Nephrol. 2006; 26:313-8.
22. Macdougall IC. CERA (continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep. 2005;4:436-40.
23. de Francisco AL, Sulowicz W, Klinger M et al. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. Int J Clin Pract. 2006; 60:1687-96.
24. Locatelli F, Villa G, Arias M et al. CERA (continuous erythropoiesis receptor activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every four weeks. Presented at the 37th Annual Meeting and Scientific Exposition of the American Society of Nephrology, St. Louis, MO: October 29-November 1, 2004. Abstract SU-PO051.
25. Dutka P, Tilocca P. CERA (continuous erythropoietin receptor activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race, or diabetic status. Presented at the American Nephrology Nurses' Association 37th National Symposium; Nashville, TN: April 2-5, 2006.
26. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov. 2003; 2:803-11.
27. Melnikova I. Anaemia therapies. Nat Rev Drug Discov. 2006; 5:627-8.
28. Liu DY, Neff TB, Guenzler V et al. Novel and beneficial pharmacodynamic properties of endogenous EPO and 'complete erythropoiesis' induced by selective HIF prolyl hydroxylase inhibitors. J Am Soc Nephrol. 2005; 16:761A.
29. Zhong H, De Marzo AM, Laughner E et al. Overexpression of hypoxia-inducible factor lalpha in common human cancers and their metastases. Cancer Res. 1999; 59:5830-5.
30. Günzler V, Muthukrishnan E, H.H. Neumayer KS et al. FG-2216 increases hemoglobin concentration in anemic patients with chronic kidney disease. J Am Soc Nephrol. 2005; 16:758A.
31. Fan A, Leuther KK, Holmes CP et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol. 2006; 34:1303-11.
32. Stead RB, Lambert J, Wessels D et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood. 2006; 108:1830-4.
33. Efficacy and safety of Hematide™ injection in the treatment of anemia in patients with chronic kidney disease. www.clinicaltrials.gov/ct/show/ NCT00314795 (accessed 2007 Feb 10).
34. Landry R, Jacobs PM, David R et al. Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients. Am J Nephrol. 2005; 25:400-10.
35. Spinowitz BS, Schwenk MH, Jacobs PM et al. The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients. Kidney Int. 2005; 68:1801-7.
36. Ferumoxytol versus oral iron in the treatment of anemia in hemodialysis patients. www.clinicaltrials.gov/ct/show/NCT00233597?order=1 (accessed 2007 Feb 10).
37. VIT45 versus oral iron in the treatment of anemia in non-dialysis dependent chronic kidney disease. www.clinicaltrials.gov/ct/show/NCT00317239? order=3 (accessed 2007 Feb 10).
38. Long term safety study of (VIT45) extension study: treatment of anemia in non-dialysis dependent chronic kidney disease, www.clinicaltrials.gov/ct/show/ NCT00317226?order=2 (accessed 2007 Feb 10).
39. Venofer package insert. Shirley, NY: American Regent, Inc; October 2005.
40. Manley HJ, McClaran ML. Determination of VIT 45 (IND#63,243 - American Regent) removal by closed loop in vitro hemodialysis system. Int J Artif Organs. 2006; 29:1062-6.
41. Dumont JA, Bitonti AJ, Clark D et al. Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J Aerosol Med. 2005; 18:294-303.
42. Ataka K, Maruyama H, Neichi T et al. Effects of erythropoietin-gene electrotransfer in rats with adenine-induced renal failure. Am J Nephrol. 2003; 23:315-23.